Consider this final episode of the 5 part all you can handle Atopic Dermatitis series the world series of dermatitis. Hall of famers Dr.s Amy Paller and Jonathan Silverberg join host Dr. Adam Friedman to review current moderate to severe AD treatment approaches and use of systemic therapies, discuss advancement on AD clinical management with use of novel target therapy, and share clinical experience with the use of biologics treatment. As we have all been thrown a curve ball in life, faculty address the growing concerns surrounding dermatology-related immunosuppressant therapy during the pandemic and how to discuss this issue with patients. Slide into home with a peak at the future therapies landscape in clinical development. The practical peals alone are worth the price of admission (um, it’s free).
Upon completion of this podcast, learners should be able to:
- Recognize the impact of target therapeutic in managing moderate to severe AD
- Consider future treatment strategies that may enhance optimal patient care
This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.
Disclosures
Amy Paller, MD – Grant/Research Support: AbbVie, Eli Lilly, Regeneron. Incyte. Consultant: Abbvie, Arena, Bausch, Bristol Myer Squibb, Dermavant, Eli Lilly, Forte, Leo, Lifemax, Pfizer, Rapt, Regeneron, and Sanofi.
Jonathan Silverberg, MD – Grant/Research Support: Galderma, Pfizer. Consultant: Abbvie, Afyx, Arena, Asana, BioMX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi. Speakers’ Bureau: Regeneron, Sanofi-Genzyme, Pfizer, Eli Lilly.
Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Podcast: Play in new window | Download
Subscribe: RSS
